Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
- J. Smolen, R. Landewé, +46 authors D. M. van der Heijde
- Medicine
- Annals of the rheumatic diseases
- 1 June 2010
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on… Expand
Treating rheumatoid arthritis to target: recommendations of an international task force
- J. Smolen, D. Aletaha, +19 authors D. M. van der Heijde
- Medicine
- Annals of the rheumatic diseases
- 9 March 2010
Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).… Expand
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- G. Jones, A. Sebba, +8 authors M. Genovese
- Medicine
- Annals of the rheumatic diseases
- 17 March 2009
Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through the AMBITION… Expand
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
- J. Smolen, F. Breedveld, +40 authors D. M. van der Heijde
- Medicine
- Annals of the rheumatic diseases
- 12 May 2015
Background Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations,… Expand
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
- J. Gómez-Reino, L. Carmona, V. R. Valverde, E. M. Mola, M. D. Montero
- Medicine
- Arthritis and rheumatism
- 1 August 2003
OBJECTIVE
The long-term safety of therapeutic agents that neutralize tumor necrosis factor (TNF) is uncertain. Recent evidence based on spontaneous reporting shows an association with active… Expand
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
- I. Solovič, M. Sester, +22 authors C. Lange
- Medicine
- European Respiratory Journal
- 7 June 2010
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory… Expand
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
- J. Gómez-Reino, L. Carmona, Miguel Angel Descalzo
- Medicine
- Arthritis and rheumatism
- 15 June 2007
OBJECTIVE
To evaluate the causes of new cases of active tuberculosis (ATB) in patients treated with tumor necrosis factor (TNF) antagonists included in the national registry BIOBADASER (Base de Datos… Expand
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
- L. Carmona, J. Gómez-Reino
- Medicine
- Arthritis research & therapy
- 18 April 2006
The aim of the present work is to compare drug survival and safety of infliximab, etanercept, and adalimumab (tumor necrosis factor [TNF] antagonists) in spondylarthritis (SpA) with those of… Expand
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases.
- A. Souto, J. R. Maneiro, J. Gómez-Reino
- Medicine
- Rheumatology
- 21 October 2015
OBJECTIVES
To assess the proportion of RA patients who discontinued biologics in world registries and health care databases and to identify causes and predictors of discontinuation.
METHODS… Expand
New Sequence Variants in HLA Class II/III Region Associated with Susceptibility to Knee Osteoarthritis Identified by Genome-Wide Association Study
- M. Nakajima, A. Takahashi, +15 authors S. Ikegawa
- Biology, Medicine
- PloS one
- 18 March 2010
Osteoarthritis (OA) is a common disease that has a definite genetic component. Only a few OA susceptibility genes that have definite functional evidence and replication of association have been… Expand